Lilly Data Point to ‘Maintenance’ Strategies for GLP-1 Weight Loss

Why It Matters

Sustaining weight loss without lifelong injections addresses a major adherence gap, potentially expanding the market for GLP‑1 obesity drugs and improving long‑term health outcomes.

Key Takeaways

• Lilly's oral Foundayo pill maintains weight loss after GLP‑1 injections
• Surmount‑Maintain showed 2‑lb loss with continued high‑dose Zepbound
• Low‑dose Zepbound led to 12‑lb regain in a year
• Wegovy patients regained only 2 lb on Foundayo after 41‑lb loss
• Zepbound patients regained 11 lb on Foundayo after 55‑lb loss

Pulse Analysis

The rapid adoption of GLP‑1 receptor agonists such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy has reshaped obesity management, delivering unprecedented average weight reductions of 40‑55 pounds. Yet the therapeutic promise is blunted by a persistent adherence problem: many patients balk at lifelong injections and experience substantial weight regain once therapy stops. Clinicians thus seek evidence‑based pathways to shift patients from intensive dosing to sustainable maintenance. Industry analysts therefore view maintenance strategies—whether dose tapering, alternative delivery routes, or oral agents—as the next frontier for sustaining the clinical gains while improving patient convenience.

In late‑2023 Lilly disclosed two pivotal trials, Surmount‑Maintain and Attain‑Maintain, that directly address this gap. The Surmount‑Maintain cohort, previously on the highest tolerable Zepbound dose, lost an additional two pounds over 12 months when the regimen was continued, whereas a reduced 5 mg dose produced a 12‑pound rebound. The Attain‑Maintain study switched patients from injectable therapy to the newly launched oral formulation, Foundayo. Wegovy‑derived patients reclaimed only two pounds, and Zepbound‑derived patients added back 11 pounds, outperforming placebo by a wide margin. The double‑blind, placebo‑controlled design published in The Lancet and Nature Medicine strengthens the findings.

These findings could recalibrate the obesity‑treatment market. An effective oral maintenance option may expand the addressable patient pool, especially among those averse to chronic injections, and give Lilly a differentiated product line that competes with Novo Nordisk’s upcoming oral semaglutide candidates. Payers are likely to favor therapies that reduce long‑term relapse, potentially reshaping reimbursement models toward maintenance dosing. Moreover, the data underscore the importance of real‑world adherence research, prompting other biotech firms to explore combination or step‑down strategies that keep weight loss durable. Should durability be confirmed, insurers may favor maintenance regimens in reimbursement frameworks.